These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 1835684)

  • 1. SCH 34826: an overview of its profile as a neutral endopeptidase inhibitor and ANF potentiator.
    Sybertz EJ
    Clin Nephrol; 1991 Oct; 36(4):187-91. PubMed ID: 1835684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutral metalloendopeptidase inhibition: a novel means of circulatory modulation.
    Sybertz EJ; Chiu PJ; Watkins RW; Vemulapalli S
    J Hypertens Suppl; 1990 Dec; 8(7):S161-7. PubMed ID: 2151333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atrial natriuretic factor-potentiating and antihypertensive activity of SCH 34826. An orally active neutral metalloendopeptidase inhibitor.
    Sybertz EJ; Chiu PJ; Vemulapalli S; Watkins R; Haslanger MF
    Hypertension; 1990 Feb; 15(2):152-61. PubMed ID: 2154404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SCH 39370, a neutral metalloendopeptidase inhibitor, potentiates biological responses to atrial natriuretic factor and lowers blood pressure in desoxycorticosterone acetate-sodium hypertensive rats.
    Sybertz EJ; Chiu PJ; Vemulapalli S; Pitts B; Foster CJ; Watkins RW; Barnett A; Haslanger MF
    J Pharmacol Exp Ther; 1989 Aug; 250(2):624-31. PubMed ID: 2547941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutral metalloendopeptidase inhibitors as ANF potentiators: sites and mechanisms of action.
    Sybertz EJ; Chiu PJ; Watkins RW; Vemulapalli S
    Can J Physiol Pharmacol; 1991 Oct; 69(10):1628-35. PubMed ID: 1838029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The blood pressure and renal responses to SCH 34826, a neutral metalloendopeptidase inhibitor, and C-ANF (4-23) in Doca-salt hypertensive rats.
    Vemulapalli S; Chiu PJ; Brown A; Griscti K; Sybertz EJ
    Life Sci; 1991; 49(5):383-91. PubMed ID: 1649942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
    Fink CA; Carlson JE; McTaggart PA; Qiao Y; Webb R; Chatelain R; Jeng AY; Trapani AJ
    J Med Chem; 1996 Aug; 39(16):3158-68. PubMed ID: 8759637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The neutral endopeptidase inhibitor, SCH 34826, reduces left ventricular hypertrophy in spontaneously hypertensive rats.
    Monopoli A; Ongini E; Cigola E; Olivetti G
    J Cardiovasc Pharmacol; 1992 Sep; 20(3):496-504. PubMed ID: 1279298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent neutral endopeptidase and ACE inhibition in experimental heart failure: renal and hormonal effects.
    Helin K
    Scand J Clin Lab Invest; 1993 Dec; 53(8):843-51. PubMed ID: 8140395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of neutral endopeptidase 24.11 in AV fistular rat model of heart failure.
    Wegner M; Hirth-Dietrich C; Stasch JP
    Cardiovasc Res; 1996 Jun; 31(6):891-8. PubMed ID: 8759244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11.
    Chatelain RE; Ghai RD; Trapani AJ; Odorico LM; Dardik BN; De Lombaert S; Lappe RW; Fink CA
    J Pharmacol Exp Ther; 1998 Mar; 284(3):974-82. PubMed ID: 9495857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action.
    Fournie-Zaluski MC; Coric P; Thery V; Gonzalez W; Meudal H; Turcaud S; Michel JB; Roques BP
    J Med Chem; 1996 Jun; 39(13):2594-608. PubMed ID: 8691458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevation of plasma atrial natriuretic peptide in rats with chronic heart failure by SCH 39370, a neutral metalloendopeptidase inhibitor.
    Tikkanen I; Helin K; Tikkanen T; Sybertz EJ; Vemulapalli S; Sariola H; Näveri H; Fyhrquist F
    J Pharmacol Exp Ther; 1990 Aug; 254(2):641-5. PubMed ID: 2143536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure.
    Trippodo NC; Robl JA; Asaad MM; Bird JE; Panchal BC; Schaeffer TR; Fox M; Giancarli MR; Cheung HS
    J Pharmacol Exp Ther; 1995 Nov; 275(2):745-52. PubMed ID: 7473162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutral endopeptidase inhibition attenuates development of hypoxic pulmonary hypertension in rats.
    Klinger JR; Petit RD; Warburton RR; Wrenn DS; Arnal F; Hill NS
    J Appl Physiol (1985); 1993 Oct; 75(4):1615-23. PubMed ID: 8282611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of SCH 34826, a neutral endopeptidase inhibitor, on hypoxic pulmonary vascular remodelling.
    Stewart AG; Sheedy W; Thompson JS; Morice AH
    Pulm Pharmacol; 1992 Jun; 5(2):111-4. PubMed ID: 1535251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-Phosphonomethyl dipeptides and their phosphonate prodrugs, a new generation of neutral endopeptidase (NEP, EC 3.4.24.11) inhibitors.
    De Lombaert S; Erion MD; Tan J; Blanchard L; el-Chehabi L; Ghai RD; Sakane Y; Berry C; Trapani AJ
    J Med Chem; 1994 Feb; 37(4):498-511. PubMed ID: 8120868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atrial natriuretic factor potentiating and hemodynamic effects of SCH 42495, a new, neutral metalloendopeptidase inhibitor.
    Watkins RW; Vemulapalli S; Chiu PJ; Foster C; Smith EM; Neustadt B; Haslanger M; Sybertz EJ
    Am J Hypertens; 1993 May; 6(5 Pt 1):357-68. PubMed ID: 8512660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
    Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA
    J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension.
    Wallis EJ; Ramsay LE; Hettiarachchi J
    Clin Pharmacol Ther; 1998 Oct; 64(4):439-49. PubMed ID: 9797801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.